参考文献/References:
[1] Li H,Li Q,Zheng Y,et al. Profiles and disparities of the global cancer and subtypes burden among adults aged 65 years and older:changing patterns in incidence and mortality,1990-2021[J]. Sci Bull (Beijing),2025,70(7):1139-1151.
[2] Wang N,Woodward M,Huffman MD,et al. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events:systematic review and meta-analysis[J]. Circ Cardiovasc Qual Outcomes,2022,15(6):e008552.
[3] Ding X,Zhang W,Li S,et al. The role of cholesterol metabolism in cancer[J]. Am J Cancer Res,2019,9(2):219-227.
[4] Siegel RL,Kratzer TB,Giaquinto AN,et al. Cancer statistics,2025[J]. CA Cancer J Clin,2025,75(1):10-45.
[5] Wilson BE,Jacob S,Yap ML,et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040:a population-based study[J]. Lancet Oncol,2019,20(6):769-780.
[6] Sarfati D,Koczwara B,Jackson C. The impact of comorbidity on cancer and its treatment[J]. CA Cancer J Clin,2016,66(4):337-350.
[7] Armenian SH,Lacchetti C,Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers:american society of clinical oncology clinical practice guideline summary[J]. J Oncol Pract,2017,13(4):270-275.
[8] Florido R,Daya NR,Ndumele CE,et al. Cardiovascular Disease Risk Among Cancer Survivors:The Atherosclerosis Risk In Communities (ARIC) Study[J]. J Am Coll Cardiol,2022,80(1):22-32.
[9] Guo K,Wang Z,Luo R,et al. Association between chronic kidney disease and cancer including the mortality of cancer patients:national health and nutrition examination survey 1999-2014[J]. Am J Transl Res,2022,14(4):2356-2366.
[10] Cheng WJ,Chiang CC,Peng MT,et al. Chronic obstructive pulmonary disease increases the risk of mortality among patients with colorectal cancer:a nationwide population-based retrospective cohort study[J]. Int J Environ Res Public Health,2021,18(16):8742.
[11] Santucci C,Mignozzi S,Levi F,et al. European cancer mortality predictions for the year 2025 with focus on breast cancer[J]. Ann Oncol,2025,36(4):460-468.
[12] 郑荣寿,陈茹,韩冰峰. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46(3):221-231.
[13] Siegel RL,Miller KD,Jemal A. Cancer statistics,2020[J]. CA Cancer J Clin,2020,70(1):7-30.
[14] Sung H,Ferlay J,Siegel RL,et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[15] Bray F,Laversanne M,Weiderpass E,et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer,2021,127(16):3029-3030.
[16] Allemani C,Matsuda T,Di Carlo V,et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3):analysis of individual records for 37?513?025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet,2018,391(10125):1023-1075.
[17] Zheng R,Zhang S,Zeng H,et al. Cancer incidence and mortality in China,2016[J]. J Natl Cancer Cent,2022,2(1):1-9.
[18] Campion O,Al Khalifa T,Langlois B,et al. Contribution of the low-density lipoprotein receptor family to breast cancer progression[J]. Front Oncol,2020,10:882.
[19] Wu C,Wang M,Shi H. Cholesterol promotes colorectal cancer growth by activating the PI3K/AKT pathway[J]. J Oncol,2022,2022:1515416.
[20] Hryniewicz-Jankowska A,Augoff K,Sikorski AF. The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer[J]. Exp Biol Med (Maywood),2019,244(13):1053-1061.
[21] Raccosta L,Fontana R,Maggioni D,et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils[J]. J Exp Med,2013,210(9):1711-1728.
[22] Kopecka J,Godel M,Riganti C. Cholesterol metabolism:at the cross road between cancer cells and immune environment[J]. Int J Biochem Cell Biol,2020,129:105876.
[23] Kim CE,Park HY,Won HJ,et al. Repression of PPARγreduces the ABCG2-mediated efflux activity of M2 macrophages[J]. Int J Biochem Cell Biol,2021,130:105895.
[24] El-Kenawi A,Dominguez-Viqueira W,Liu M,et al. Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer[J]. Cancer Res,2021,81(21):5477-5490.
[25] Pan Z,Wang K,Wang X,et al. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRαre-expression[J]. Mol Cancer,2022,21(1):77.
[26] Li D,Yao Y,Rao Y,et al. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2022,41(1):116.
[27] Wang Q,Cao Y,Shen L,et al. Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs[J]. Sci Adv,2022,8(34):eabq4722.
[28] Shao WQ,Li YT,Zhou X,et al. Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC[J]. Mol Cell Biochem,2025,480(3):1807-1818.
[29] Hartmann P,Trufa DI,Hohenberger K,et al. Contribution of serum lipids and cholesterol cellular metabolism in lung cancer development and progression[J]. Sci Rep,2023,13(1):5662.
[30] Paul B,Lewinska M,Andersen JB. Lipid alterations in chronic liver disease and liver cancer[J]. JHEP Rep,2022,4(6):100479.
[31] Zhang D,Hu RH,Cui XM,et al. Lipid levels and insulin resistance markers in gastric cancer patients:diagnostic and prognostic significance[J]. BMC Gastroenterol,2024,24(1):373.
[32] Li X,Liu ZL,Wu YT,et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy[J]. Lipids Health Dis,2018,17(1):91.
[33] Wang X,Wang Y,Wang M,et al. The association between serum lipid levels and histological type of breast cancer[J]. Eur J Med Res,2022,27(1):154.
[34] Alomar SA,G?man MA,Prabahar K,et al. The effect of tamoxifen on the lipid profile in women:A systematic review and meta-analysis of randomized controlled trials[J]. Exp Gerontol,2022,159:111680.
[35] Bérczi B,Farkas N,Hegyi P,et al. Aromatase inhibitors and plasma lipid changes in postmenopausal women with breast cancer:a systematic review and meta-analysis[J]. J Clin Med,2024,13(6):1818.
[36] Costa A,Pittorru R,Caocci G,et al. The direct and indirect effects of tyrosine kinase inhibitors on the cardiovascular system in chronic myeloid leukemia.[J]. Hemato,2023,4(3):207-226.
[37] Cedó L,Reddy ST,Mato E,et al. HDL and LDL:Potential New Players in Breast Cancer Development[J]. J Clin Med,2019,8(6):853.
[38] Lin Q,Liu W,Xu S,et al. Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer[J]. Arch Gynecol Obstet,2022,305(3):683-691.
[39] Hong TT,Shen D,Chen XP,et al. Preoperative serum lipid profile and outcome in nonmetastatic colorectal cancer[J]. Chronic Dis Transl Med,2016,2(4):241-249.
[40] Kim S,Kim G,Cho SH,et al. Association between total cholesterol levels and all-cause mortality among newly diagnosed patients with cancer[J]. Sci Rep,2024,14(1):58.
[41] Integrative Cardio-Oncology Society of China Anti-Cancer Association. [Chinese expert consensus on lipid management in patients with malignancy][J]. Zhonghua Zhong Liu Za Zhi,2021,43(10):1043-1053.
[42] Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2019,73(24):3168-3209.
[43] de Jesus M,Mohammed T,Singh M,et al. Etiology and management of dyslipidemia in patients with cancer.[J] Front Cardiovasc Med,2022,9:892335.
[44] 中国乳腺癌内分泌治疗多学科管理血脂异常管理共识专家组,徐兵河. 绝经后早期乳腺癌患者血脂异常管理的中国专家共识[J]. 中华肿瘤杂志,2017,39(1):72-77.
[45] Mao W,Cai Y,Chen D,et al. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer[J]. JCI Insight,2022,7(18):e161940.
[46] Kansal V,Burnham AJ,Kinney BLC,et al. Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models[J]. J Immunother Cancer,2023,11(1):e005940.
[47] Liu X,Bao X,Hu M,et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer[J]. Nature,2020,588(7839):693-698.
[48] Zhang T,Qin Q,Cole S,et al. A phaseⅡstudy bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC)[J]. J Clin Oncol, 2025,43(5_suppl):S612.
[49] Gu J,Zhu N,Li HF,et al. Ezetimibe and cancer:is there a connection?[J] Front Pharmacol,2022,13:831657.
[50] Burstein HJ,Lacchetti C,Anderson H,et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer:ASCO Clinical Practice Guideline Focused Update[J]. J Clin Oncol,2019,37(5):423-438.
[51] Fogli S,Del Re M,Curigliano G,et al. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors[J]. Cancer Treat Rev,2019,74:21-28.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(9):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(9):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[3]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(9):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[4]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[5]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(9):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[6]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[7]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[8]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(9):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
[9]李开炜 彭汶婷 祝烨.降脂药物与认知功能下降的研究进展[J].心血管病学进展,2024,(3):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
LI Kaiwei,PENG Wenting,ZHU Ye.Lipid-Lowering Drugs and Cognitive Function Decline[J].Advances in Cardiovascular Diseases,2024,(9):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
[10]乔斌超 贾永平.小干扰RNA降脂药物英克司兰研究进展[J].心血管病学进展,2024,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]
QIAO Binchao,JIA Yongping.Small Interfering RNA Lipid-Lowering Drug of Inclisiran[J].Advances in Cardiovascular Diseases,2024,(9):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]